Hypertension Management: an Update

Overview

Journal Am Health Drug Benefits

Date 2014 Aug 16

PMID 25126308

Citations 42

Authors

Quang Nguyen

Joann Dominguez

Loida Nguyen

Nageshwara Gullapalli

Affiliations

Soon will be listed here.

Abstract

Hypertension is a significant and costly public health problem. It is a major, but modifiable contributor for the development of cardiovascular disease. Randomized controlled trials have shown that controlling hypertension reduces the risk of stroke, coronary artery disease, congestive heart failure, end-stage renal disease, peripheral vascular disease, as well as overall mortality. The risk of developing these hypertension-related complications is continuous, starting at a blood pressure level as low as 115/75 mm Hg. Despite the inherent health risks associated with uncontrolled hypertension, elevated blood pressure remains inadequately treated in the majority of patients. This article reviews guidelines for optimal evaluation of hypertension and current therapeutic options available to combat this common yet pervasive disease.

Citing Articles

Arterial Hypertension: Novel Pharmacological Targets and Future Perspectives.

Popa I, Clim A, Pinzariu A, Lazar C, Popa S, Tudorancea I J Clin Med. 2024; 13(19).

PMID: 39407987 PMC: 11478071. DOI: 10.3390/jcm13195927.

Targeting the sympathetic nervous system with the selective imidazoline receptor agonist moxonidine for the management of hypertension: an international position statement.

Schlaich M, Tsioufis K, Taddei S, Ferri C, Cooper M, Sindone A J Hypertens. 2024; 42(12):2025-2040.

PMID: 38747424 PMC: 11556879. DOI: 10.1097/HJH.0000000000003769.

Sakuranetin as a Potential Regulator of Blood Pressure in Spontaneously Hypertensive Rats by Promoting Vasorelaxation through Calcium Channel Blockade.

Shin S, Park J, Choi H, Bu Y, Lee K Biomedicines. 2024; 12(2).

PMID: 38397948 PMC: 10887318. DOI: 10.3390/biomedicines12020346.

Mindful breathing as an effective technique in the management of hypertension.

Natarajan A, Emir-Farinas H, Su H Front Physiol. 2024; 14:1339873.

PMID: 38321984 PMC: 10844494. DOI: 10.3389/fphys.2023.1339873.

Polypharmacy among patients with hypertension attending primary healthcare centres.

Alsanosi S, Mousa A, Ahmadini H, Qadhi R, Ikram N, Felemban A Ann Med Surg (Lond). 2023; 85(6):2545-2549.

PMID: 37363582 PMC: 10289761. DOI: 10.1097/MS9.0000000000000818.

References

Moser M, Setaro J . Clinical practice. Resistant or difficult-to-control hypertension. N Engl J Med. 2006; 355(4):385-92. DOI: 10.1056/NEJMcp041698. View

Appel L, Champagne C, Harsha D, Cooper L, Obarzanek E, Elmer P . Effects of comprehensive lifestyle modification on blood pressure control: main results of the PREMIER clinical trial. JAMA. 2003; 289(16):2083-93. DOI: 10.1001/jama.289.16.2083. View

Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B . Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003; 348(14):1309-21. DOI: 10.1056/NEJMoa030207. View

. Medical Research Council trial of treatment of hypertension in older adults: principal results. MRC Working Party. BMJ. 1992; 304(6824):405-12. PMC: 1995577. DOI: 10.1136/bmj.304.6824.405. View

Vasan R, Beiser A, Seshadri S, Larson M, Kannel W, DAgostino R . Residual lifetime risk for developing hypertension in middle-aged women and men: The Framingham Heart Study. JAMA. 2002; 287(8):1003-10. DOI: 10.1001/jama.287.8.1003. View

Wiysonge C, Bradley H, Mayosi B, Maroney R, Mbewu A, Opie L . Beta-blockers for hypertension. Cochrane Database Syst Rev. 2007; (1):CD002003. DOI: 10.1002/14651858.CD002003.pub2. View

Che Q, Schreiber Jr M, Rafey M . Beta-blockers for hypertension: are they going out of style?. Cleve Clin J Med. 2009; 76(9):533-42. DOI: 10.3949/ccjm.76a.09030. View

. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group. JAMA. 1991; 265(24):3255-64. View

Villamil A, Chrysant S, Calhoun D, Schober B, Hsu H, Matrisciano-Dimichino L . Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide. J Hypertens. 2006; 25(1):217-26. DOI: 10.1097/HJH.0b013e3280103a6b. View

10.

Goodfriend T, Calhoun D . Resistant hypertension, obesity, sleep apnea, and aldosterone: theory and therapy. Hypertension. 2004; 43(3):518-24. DOI: 10.1161/01.HYP.0000116223.97436.e5. View

11.

. Effects of treatment on morbidity in hypertension. Results in patients with diastolic blood pressures averaging 115 through 129 mm Hg. JAMA. 1967; 202(11):1028-34. View

12.

. The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Arch Intern Med. 1997; 157(21):2413-46. DOI: 10.1001/archinte.157.21.2413. View

13.

Sarafidis P, Bakris G . Resistant hypertension: an overview of evaluation and treatment. J Am Coll Cardiol. 2008; 52(22):1749-57. DOI: 10.1016/j.jacc.2008.08.036. View

14.

Jamerson K, Weber M, Bakris G, Dahlof B, Pitt B, Shi V . Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med. 2008; 359(23):2417-28. DOI: 10.1056/NEJMoa0806182. View

15.

. Screening for high blood pressure: U.S. Preventive Services Task Force reaffirmation recommendation statement. Ann Intern Med. 2007; 147(11):783-6. DOI: 10.7326/0003-4819-147-11-200712040-00009. View

16.

Uresin Y, Taylor A, Kilo C, Tschope D, Santonastaso M, Ibram G . Efficacy and safety of the direct renin inhibitor aliskiren and ramipril alone or in combination in patients with diabetes and hypertension. J Renin Angiotensin Aldosterone Syst. 2008; 8(4):190-8. DOI: 10.3317/jraas.2007.028. View

17.

. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002; 288(23):2981-97. DOI: 10.1001/jama.288.23.2981. View

18.

Neal B, Macmahon S, Chapman N . Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Blood Pressure Lowering Treatment Trialists' Collaboration. Lancet. 2000; 356(9246):1955-64. DOI: 10.1016/s0140-6736(00)03307-9. View

19.

Heran B, Wong M, Heran I, Wright J . Blood pressure lowering efficacy of angiotensin receptor blockers for primary hypertension. Cochrane Database Syst Rev. 2008; (4):CD003822. PMC: 6669255. DOI: 10.1002/14651858.CD003822.pub2. View

20.

Parving H, Persson F, Lewis J, Lewis E, Hollenberg N . Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med. 2008; 358(23):2433-46. DOI: 10.1056/NEJMoa0708379. View